First Patient Enrolls in Phase 2 Trial of ABX464, Potential Ulcerative Colitis Treatment

First Patient Enrolls in Phase 2 Trial of ABX464, Potential Ulcerative Colitis Treatment
A first patient has been enrolled in a proof-of-concept clinical trial of ABX464 as a possible treatment for people with moderate-to-severe active ulcerative colitis, its developer, Abivax, announced in a press release. The patient was enrolled at the University Hospitals Leuven, Belgium. The trial involves 17 other centers in seven European countries besides Belgium: France, Germany, Poland, Hungary, Czech Republic, Spain and Austria. ABX464 was first developed to be an oral, first-in-class, small molecule that might lessen or eliminate the HIV viral reservoirs, with the potential to reduce for the long term the viral load of HIV-patients. It is being tested in ulcerative colitis because it has shown the possibility of being a strong anti-inflammatory agent. "The opportunity to study ABX464 in inflammatory bowel disease (IBD) inflammation came from clinical and preclinical anti-inflammatory effects observed in our research on this drug-candidate for treatment of HIV infection, where the HIV reservoir is the source of chronic inflammation,” Jean-Marc Steens, chief medical officer at Abivax said in the release. ABX464's efficacy has already been demonstrated in studies using IBD models. In lab-grown human immune cells, scientists reported higher-than-usual levels of a specific protein (interleukin 22) and small RNA molecule (miR124), known mediators of the body's immune response. This finding further supports ABX464 anti-inflammatory properties, and its potential benefit to people with ulcerative colitis, an inflammation-based disease. ABX464-1
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *